Acta Med. 2010, 53: 125-129

https://doi.org/10.14712/18059694.2016.71

The Counter-Regulation of Atherogenesis: a Role for Interleukin-33

Pavel Kuneša,b, Zdeňka Holubcováa, Martina Koláčkováb, Jan Krejsekb

aCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Cardiac Surgery, Hradec Králové, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic

Received March 19, 2010
Accepted July 5, 2010

References

1. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12:178–180. <https://doi.org/10.1038/nm1343>
2. Aoki S, Hayakawa M, Ozaki H, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010; 335:75–81. <https://doi.org/10.1007/s11010-009-0244-9>
3. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52:2166–2174. <https://doi.org/10.1016/j.jacc.2008.09.027> <PubMed>
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3:401–10. <https://doi.org/10.1038/nrc1093>
5. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukocyte Biol 2007; 81:1–5. <https://doi.org/10.1189/jlb.0306164>
6. Binder CJ, Hartvigsen K, Chang MK, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114:427–37. <https://doi.org/10.1172/JCI200420479>
7. Binder CJ, Hörkkö S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9:736–743. <https://doi.org/10.1038/nm876>
8. Binder CJ, Shaw PX, Chang MK, et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005; 46:1353–1363. <https://doi.org/10.1194/jlr.R500005-JLR200>
9. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104:282–7. <https://doi.org/10.1073/pnas.0606854104> <PubMed>
10. Choi YS, Choi HJ, Min JK, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114:3117–3126. <https://doi.org/10.1182/blood-2009-02-203372>
11. Fagundes CT, Amaral FA, Souza ALS, et al. ST2, an IL-1R family member, attenuates inflammation and lethality after intestinal ischemia and reperfusion. J Leukocyte Biol 2007; 81:492–499. <https://doi.org/10.1189/jlb.0606422>
12. Hayakawa H, Hayakawa M, Kume A, Tominaga S-i. Soluble ST2 blocks interleukin- 33 signaling in allergic airway inflammation. J Biol Chem 2007; 282: 26369–26380. <https://doi.org/10.1074/jbc.M704916200>
13. Karvonen J, Päivänsalo M, Kesäniemi YA, et al. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003; 108:2107–2112. <https://doi.org/10.1161/01.CIR.0000092891.55157.A7>
14. Krebs P, Scandella E, Bolinger B, Engeler D, Miller S, Ludewig B. Chronic immune reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2007; 27: 2206–13. <https://doi.org/10.1161/ATVBAHA.107.141846>
15. Küchler AM, Pollheimer J, Balogh J, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008; 173:1229–42. <https://doi.org/10.2353/ajpath.2008.080014> <PubMed>
16. Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181:4780–4790. <https://doi.org/10.4049/jimmunol.181.7.4780>
17. Matsuyama Y, Okazaki H, Tamemoto H, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37:18–25. <https://doi.org/10.3899/jrheum.090492>
18. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22:3595–606. <https://doi.org/10.1096/fj.08-112201> <PubMed>
19. Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205:339–46. <https://doi.org/10.1084/jem.20071868> <PubMed>
20. Moon BG, Takaki S, Miyake K, et al. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol 2004; 172: 6020–6029. <https://doi.org/10.4049/jimmunol.172.10.6020>
21. Mor A, Planer D, Luboshits G, et al. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arteriol Thromb Vasc Biol 2007; 27:893–900. <https://doi.org/10.1161/01.ATV.0000259365.31469.89>
22. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008; 54:752–756. <https://doi.org/10.1373/clinchem.2007.096560>
23. Murphy GEJ, Xu D, Liew FY, McInnes IB. Role of interleukin 33 in human immunopathology. Ann Rheum Dis 2010; 69(Suppl.1): i43–i47. <https://doi.org/10.1136/ard.2009.120113>
24. Palinski W, Hörkkö S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98:800–814. <https://doi.org/10.1172/JCI118853> <PubMed>
25. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A 1995; 92:821–825. <https://doi.org/10.1073/pnas.92.3.821> <PubMed>
26. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000; 80:99–115. <https://doi.org/10.1038/labinvest.3780013>
27. Pushparaj PN, Tay HK, H’ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009; 106: 9773–9778. <https://doi.org/10.1073/pnas.0901206106> <PubMed>
28. Read S, Powrie F. CD4+ regulatory T cells. Curr Opin Immunol 2001; 13: 644–649. <https://doi.org/10.1016/S0952-7915(01)00273-4>
29. Rehman SU, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008; 52:1458–65. <https://doi.org/10.1016/j.jacc.2008.07.042>
30. Sämpi M, Ukkola O, Päivänsalo M, Kesäniemi YA, Binder CJ, Hörkkö S. Plasma interleukin-5 levels are related to antibodies binding to oxidized low-density lipoprotein and to decreased subclinical atherosclerosis. J Am Coll Cardiol 2008; 52:1370–8. <https://doi.org/10.1016/j.jacc.2008.06.047>
31. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007; 117:1538–1549. <https://doi.org/10.1172/JCI30634> <PubMed>
32. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479–90. <https://doi.org/10.1016/j.immuni.2005.09.015>
33. Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 2008; 172:1500–8. <https://doi.org/10.2353/ajpath.2008.070776> <PubMed>
34. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105:1731–1740. <https://doi.org/10.1172/JCI8472> <PubMed>
35. Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109:2186–90. <https://doi.org/10.1161/01.CIR.0000127958.21003.5A>
36. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83:835–70. <https://doi.org/10.1152/physrev.2003.83.3.835>
37. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th)1→Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice. J Clin Invest 1998; 101:1717–25. <https://doi.org/10.1172/JCI1216> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive